Get the Stockscreener App
7.06
0.14%
0.010
After Hours:
7.18
0.12
+1.70%
Wave Life Sciences Ltd stock is traded at $7.06, with a volume of 3.35M.
It is up +0.14% in the last 24 hours and up +6.65% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$7.05
Open:
$7.05
24h Volume:
3.35M
Relative Volume:
0.79
Market Cap:
$1.36B
Revenue:
$71.80M
Net Income/Loss:
$-183.59M
P/E Ratio:
-6.6964
EPS:
-1.0543
Net Cash Flow:
$-189.73M
1W Performance:
-3.42%
1M Performance:
+6.65%
6M Performance:
-14.94%
1Y Performance:
-8.55%
1-Day Range:
$6.98
$7.175
1-Week Range:
$6.865
$7.56
52-Week Range:
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
7.06 | 1.45B | 71.80M | -183.59M | -189.73M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $43 - Moomoo
Canaccord lowers Wave Life Sciences stock price target on valuation By Investing.com - Investing.com Canada
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)? - simplywall.st
Wave Life Sciences Signals Momentum In Earnings Call - TipRanks
Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO - Barchart.com
RBC Capital Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
WVE Maintained by Truist Securities -- Price Target Lowered to $15 - GuruFocus
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $36 - Moomoo
Truist Financial Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $15 - Moomoo
Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Wave Life Sciences: Q1 Earnings Snapshot - theheraldreview.com
Truist assumes coverage on Wave Life Sciences stock with buy rating - Investing.com
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Advancements - GuruFocus
WAVE Life Sciences Q1 2026 Earnings Call Transcript - MarketBeat
Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns - simplywall.st
MSN Money - MSN
Clear Street Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress By Investing.com - Investing.com South Africa
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress - Investing.com Canada
Wave (WVE) Q1 2025 Earnings Call Transcript - The Motley Fool
WAVE Life Sciences Q1 Earnings Call Highlights - Yahoo Finance
BofA cuts Wave Life Sciences stock price target on trial focus - Investing.com
Is WAVE Life Sciences (WVE) Overvalued After Q1 2026 8-K? GF Sco - GuruFocus
BofA cuts Wave Life Sciences stock price target on trial focus By Investing.com - Investing.com India
Clear Street cuts Wave Life Sciences stock price target on obesity trial outlook - Investing.com Canada
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast - Investing.com
Wave Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Wave Life Sciences (WVE) Reports Strong Q1 Revenue and Advances WVE-007 Development - GuruFocus
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Wave Life Sciences 1Q Research and Development Expenses $47.4M >WVE - Moomoo
Q1 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates - ChartMill
Wave Life Sciences Reports Q1 Results, Advances RNA Pipeline - TipRanks
WAVE LIFE SCIENCES ($WVE) Releases Q1 2026 Earnings - Quiver Quantitative
Wave Life Sciences (WVE) lifts Q1 revenue, trims loss with strong cash runway - Stock Titan
Earnings Flash (WVE) Wave Life Sciences Posts Q1 Net Loss $0.13 a Share, vs. FactSet Est of $0.32 Loss a Share - marketscreener.com
Earnings Flash (WVE) Wave Life Sciences Ltd. Reports Q1 Revenue $38.2M, vs. FactSet Est of $8.5M - marketscreener.com
As of March 31, 2026, Wave Life Sciences Pte. Ltd (NASDAQ: WVE) announced its cash and cash equivalents reserves reached $544.6 millions. - Bitget
Wave Life Sciences (Nasdaq: WVE) Q1 2026 results highlight $544.6M cash runway - Stock Titan
Earnings Flash (WVE) Wave Life Sciences Ltd. Reports Q1 Revenue $38.2M, Vs. FactSet Est of $8.5M - Moomoo
Wave says obesity drug trial is on track for 2Q after FDA acceptance - Stock Titan
Wave Life Sciences (WVE) price target decreased by 20.34% to 28.29 - MSN
Wave hits 52-week low as analysts react to obesity drug data - MSN
Wave Life Sciences faces earnings test after obesity setback By Investing.com - Investing.com Nigeria
Wave Life Sciences announces $250M public offering and pre-funded warrants - MSN
WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving AverageShould You Sell? - MarketBeat
WAVE Life Sciences (WVE) Projected to Post Earnings on Tuesday - MarketBeat
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin - Barchart
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Wave Life Sciences Ltd Stock (WVE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):